| Active Not Recruiting | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03210714 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi NCT03213652 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist NCT03233204 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213704 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or NCT02304458 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Withdrawn | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors NCT02011126 | Children's Oncology Group | Phase 2 |
| Completed | Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies NCT02116777 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Withdrawn | Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue i NCT01795430 | City of Hope Medical Center | N/A |
| Completed | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma NCT01614795 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01154816 | Children's Oncology Group | Phase 2 |
| Completed | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced NCT01154452 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Collecting and Storing Biological Samples From Patients With Ewing Sarcoma NCT00899990 | Children's Oncology Group | — |
| Completed | Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating You NCT00516295 | National Cancer Institute (NCI) | Phase 2 |
| Completed | IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectoder NCT00609141 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagn NCT00638898 | City of Hope Medical Center | Phase 1 |
| Completed | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in T NCT00536601 | Roswell Park Cancer Institute | N/A |
| Completed | Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) NCT00330421 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ixabepilone in Treating Young Patients With Refractory Solid Tumors NCT00331643 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas NCT00101270 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma NCT00112463 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatme NCT00091182 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors NCT00093821 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma NCT00048984 | Children's Oncology Group | — |
| Completed | Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood NCT00030667 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas NCT00012181 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymph NCT00004241 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Irinotecan in Treating Children With Refractory Solid Tumors NCT00004078 | Children's Oncology Group | Phase 2 |